View of PSMA-directed radioligand therapy (PSMA-RLT) with Lutetium-177 (177Lu-PSMA) as a treatment to metastatic resistant prostate cancer: a systematic review

Return to Issue Details PSMA-directed radioligand therapy (PSMA-RLT) with Lutetium-177 (177Lu-PSMA) as a treatment to metastatic resistant prostate cancer: a systematic review Download Download PDF